<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641949</url>
  </required_header>
  <id_info>
    <org_study_id>lbnp_methoxy_fent_2019</org_study_id>
    <nct_id>NCT04641949</nct_id>
  </id_info>
  <brief_title>Methoxyflurane and Fentanyl in LBNP</brief_title>
  <official_title>Methoxyflurane and Fentanyl in the Lower Body Negative Pressure Model of Hypovolemia in Healthy Volunteers; a Randomized, Placebo-controlled Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-centre, placebo-controlled, crossover study on healthy volunteers&#xD;
      aiming to explore non-inferiority of methoxyflurane and fentanyl compared to placebo on the&#xD;
      tolerance to hypovolemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will explore the effects of fentanyl and methoxyflurane versus placebo (NaCl;&#xD;
      saline) on the hemodynamic response to hypovolemia in healty volunteers. Hypovolemia will be&#xD;
      induced in the &quot;lower body negative pressure&quot; model. XX healthy volunteers will be exposed to&#xD;
      inhaled methoxyflurane, 3 ml or intravenous fentanyl, XX mg or placebo in a randomized order&#xD;
      (cross-over) at least 3 days apart.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo controlled, crossover study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both drug interventions (intravenous fentanyl and inhaled methoxyflurane) will have NaCl placebo comparators. As the methoxyflurane has a characteristic smell, some drops of methoxyflurane will be placed on the exterior of the placebo methoxyflurane inhalation devices. Further, the subjects will rinse the mouth with a mouthwash shortly before inhalation to cover the taste of methoxyflurane.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Measured continuously during LBNP-exposure.</time_frame>
    <description>Cardiac output as measured by suprasternal Doppler and/ or non-invasive (volume clamp) pulse contour analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hemodynamic decompensation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Time from start LBNP to symtomps or signs of hemodynamic decompensation (and termination of LBNP); defined by:&#xD;
Symptoms of pre-syncope (light-headedness, nausea or sweating)&#xD;
Mean arterial pressure-reduction to less than 75% of baseline for &gt;3 s&#xD;
Heart rate-reduction to less than 75% baseline for &gt;3 s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>Measured continuously during LBNP-exposure.</time_frame>
    <description>Change in mean arterial blood pressure with increasing LBNP, as measured by the volume-clamp method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke volume</measure>
    <time_frame>Measured continuously during LBNP-exposure.</time_frame>
    <description>Change in cardiac stroke volume with increasing LBNP, as measured by suprasternal Doppler and/ or the volume-clamp method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hypovolemia</condition>
  <condition>Cardiac Output, Low</condition>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Methoxyflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalation methoxyflurane 99,9%, 3 ml, single dose. Intravenous NaCl 9 mg/ml, XX ml, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous NaCl 9 mg/ml, XX ml, single dose. Inhalation NaCl 9 mg/ml, 3 ml, single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lower body negative pressure (LBNP)</intervention_name>
    <description>LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Methoxyflurane</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be at least 18 years of age.&#xD;
&#xD;
          -  Must be below 65 years of age.&#xD;
&#xD;
          -  Signed informed consent and expected cooperation for the study and follow up must be&#xD;
             obtained and documented according to ICH GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition limiting physical excertional capacity or requiring regular&#xD;
             medication (allergy and oral contraceptives excepted)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of syncope (syncope of presumed vasovagal nature with known precipitating&#xD;
             factor excepted)&#xD;
&#xD;
          -  Any known cardiac arrhythmia&#xD;
&#xD;
          -  History of renal disease&#xD;
&#xD;
          -  History of liver disease&#xD;
&#xD;
          -  Previous substance abuse&#xD;
&#xD;
          -  Allery or known serious side-effects to opioids or methoxyflurane&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars Øivind Høiseth, MD, PhD</last_name>
    <phone>+47 22119690</phone>
    <email>lars.oivind.hoiseth@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harald Lenz, MD, PhD</last_name>
    <phone>+47 23070000</phone>
    <email>uxhanz@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0586</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Øivind Høiseth, MD, PhD</last_name>
      <phone>90749409</phone>
      <email>lars.oivind.hoiseth@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Øivind Høiseth</investigator_full_name>
    <investigator_title>Overlege, PhD</investigator_title>
  </responsible_party>
  <keyword>Methoxyflurane</keyword>
  <keyword>Fentanyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Output, Low</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

